IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval In Brazil; $6.6M In Sales Expected In Brazilian Market Over The Next Five Years Per Distribution Agreement Guarantees
Portfolio Pulse from Happy Mohamed
IceCure Medical Ltd. (NASDAQ:ICCM) has received regulatory approval from the Brazilian Health Regulatory Agency for its ProSense Cryoablation System. The company expects $6.6 million in sales in the Brazilian market over the next five years. The ProSense system is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal. The approval is expected to translate into near-term revenues due to strong demand in Brazil, which has an urgent need for minimally invasive cancer treatments.
September 05, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure Medical's ProSense Cryoablation System has received regulatory approval in Brazil, which is expected to generate $6.6 million in sales over the next five years. This approval could lead to near-term revenues for the company.
The regulatory approval of IceCure Medical's ProSense Cryoablation System in Brazil is a significant milestone for the company. This approval opens up a new market for the company, which is expected to generate substantial revenues over the next five years. Given the urgent need for minimally invasive cancer treatments in Brazil, there is likely to be strong demand for the ProSense system, which could positively impact IceCure's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100